Preparation and dissolution characteristic evaluation of carvedilol-Kollicoat IR solid dispersions with HPMC and MC as combined carriers

Preparation and dissolution characteristic evaluation of carvedilol-Kollicoat IR solid dispersions with HPMC and MC as combined carriers

Journal Pre-proof Preparation and dissolution characteristic evaluation of carvedilol-Kollicoat IR solid dispersions with HPMC and MC as combined carr...

2MB Sizes 0 Downloads 56 Views

Journal Pre-proof Preparation and dissolution characteristic evaluation of carvedilol-Kollicoat IR solid dispersions with HPMC and MC as combined carriers Ziyue Xi, Wei Zhang, Zisen Gao, Luyao Xie, Lu Chen, Mingshu Cui, Yanru Xi, Lu Xu PII:

S0032-5910(19)30924-6

DOI:

https://doi.org/10.1016/j.powtec.2019.10.095

Reference:

PTEC 14862

To appear in:

Powder Technology

Received Date: 19 April 2019 Revised Date:

7 September 2019

Accepted Date: 25 October 2019

Please cite this article as: Z. Xi, W. Zhang, Z. Gao, L. Xie, L. Chen, M. Cui, Y. Xi, L. Xu, Preparation and dissolution characteristic evaluation of carvedilol-Kollicoat IR solid dispersions with HPMC and MC as combined carriers, Powder Technology (2019), doi: https://doi.org/10.1016/j.powtec.2019.10.095. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2019 Published by Elsevier B.V.

1

Preparation and Dissolution Characteristic Evaluation of

2

Carvedilol-Kollicoat IR Solid Dispersions with HPMC and MC

3

as Combined Carriers

4

Ziyue Xia, Wei Zhanga, Zisen Gaob, Luyao Xiea, Lu Chena, Mingshu Cuia, Yanru Xia, Lu Xua*

5

a. School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016,

6

China;

7

b. Key Laboratory of Structure-Based Drug Design Discovery of Ministry of Education, Shenyang

8

Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China;

9

* Correspondence: [email protected]; Tel.: 024-43520583

10

Abstract

11

In this study, the abilities of hydroxypropyl methylcellulose (HPMC) and methylcellulose (MC)

12

as nonionic surfactants to improve the dissolution rate of carvedilol solid dispersions (CAR SDs) with

13

Kollicoat IR as a carrier were clearly demonstrated. CAR SDs were prepared using the solvent

14

evaporation method, and their physicochemical properties were characterized by scanning electron

15

microscopy (SEM) and X-ray diffraction (XRD). The results suggested that CAR in SDs existed in an

16

amorphous form. In vitro dissolution experiments and molecular docking (MD) simulations were

17

conducted to confirm the storage stability of CAR SDs. In order to study the mechanism of

18

solubilization ability, molar solubilization ratio (MSR) and micelle-water partition coefficient (Kmic)

19

were calculated. The results showed that the MSR and logKmic values of MC/Kollicoat IR 1:3 were

20

around 30-fold higher than the single surfactants. Above all, HPMC and MC have great potentials to

21

improve the dissolution characteristics of CAR-Kollicoat IR SDs.

22

Keywords: Carvedilol, Kollicoat IR, Solid dispersion, Surfactant, Solubilization mechanism

23

1. Introduction

24

Carvedilol

(Figure

1a)

(CAR,

{1-[carbazolyl-(4)-oxy]-3-[2-methoxyphenoxyethylamino]

25

propanol-(2)}) is a non-selective ɑ, β1, and β2 adrenergic receptor antagonist with antioxidant

26

properties. Therefore, CAR has been used in clinical practice for the treatment of cardiovascular

27

diseases (hypertension, congestive heart failure, or myocardial infarction) [1]. As a biopharmaceutical 1

28

classification system (BCS) class II drug, CAR has high membrane permeability, slow dissolution rate

29

because of low water solubility, and is administered as a large oral dose [2]. Its low solubility may

30

hinder the absorption of the drug in the small intestine and colon. Thus, it is necessary to improve the

31

dissolution rate of CAR. At present, methods applied to improve the dissolution rate of insoluble drugs

32

include solid dispersions (SDs) [3-4], liquisolid compacts [5-6], and self-emulsion systems [7-8].

33

Among these methods, solid dispersion is one of the most effective methods.

34

In the past five decades, solid dispersion techniques have been continuously developed and have

35

become one of the most effective approaches to improve the dissolution rate and bioavailability of

36

poorly water-soluble drugs [3]. Traditional single polymers such as hydroxypropyl methyl cellulose

37

(HPMC), hydroxypropyl methylcellulose phthalate (HPMCP), and polyvinylpyrrolidone (PVP), and

38

novel materials including Kollidon K-30, Kollidon CL, and Soluplus® have been widely used as

39

carriers in solid dispersion to improve the dissolution and to prevent crystallization of drugs. With the

40

development of SDs, binary polymer systems were also used as carriers in the preparation of SDs [9] to

41

improve stability significantly compared to single carriers. Moreover, binary carriers with the addition

42

of surfactants based on the single polymer have been shown to enhance bioavailability by solubilizing

43

and supersaturating drugs in the gastrointestinal88i fluids. In recent studies, CAR SDs were prepared

44

using many types of polymers as carriers including single polymers like HPMC [10], HPMCAS [11],

45

and Soluplus® [3], or binary polymers such as Eudragit /Tween 80 and PVP/Tween 80 [2]. Despite the

46

existence of some relevant studies, research into the surfactants HPMC and MC as combined carriers

47

added to CAR SDs to improve dissolution of poorly water-soluble drugs and the relative mechanism of

48

solubilization is still rare.

49

Herein, CAR SDs were prepared using the solvent evaporation method with different ratios of the

50

surfactants and Kollicoat IR (Figure 1d). HPMC (Figure 1b) and methyl cellulose (MC, Figure 1c)

51

were chosen as nonionic surfactants. X-Ray Diffractometry (XRD) and Scanning Electron Microscopy

52

(SEM) were used to characterize the solid-state of CAR. In vitro release performance was applied to

53

evaluate the dissolution ability and storage stability of CAR SDs. Furthermore, to study the mechanism,

54

several kinetic models were fitted to confirm the effect of the surfactant incorporated with SDs. With

55

the molecular docking and kinetic models studies of solid dispersion, the solubility mechanism of CAR

56

SDs could be better understood, which provides insights into the theory of drug release. Additionally,

57

the critical micelle concentration (CMC), molar solubilization ratio (MSR), and micellar-water 2

58

partition coefficient Kmic were calculated for the surfactants. Overall, the results, highlighted here,

59

provided new insights into surfactants addition for future design of efficient poorly water-soluble drug

60

delivery systems. As far as is known by the authors of this study, this is the first time that CAR solid

61

dispersions were prepared with Kollicoat IR and the nonionic surfactants HPMC and MC as

62

combined carriers.

63

2. . Materials and methods

64

2.1. Materials

65

Carvedilol with purity of more than 99% was purchased from Jiuding Chemical Reagent

66

Corporation, Shanghai, China; Kollicoat IR was obtained from BASF, Germany; hydroxypropyl

67

methylcellulose (HPMC) E5 was obtained from Sunhere Pharmaceutical Excipients Chemical Reagent

68

Corporation, Anhui, China; and methylcellulose 55 HD100 (MC) was supplied by Head Chemical

69

Reagent Corporation, Shangdong, China. Other chemical agents were obtained from Yu Wang

70

Chemical Reagent Corporation, Shangdong, China. All other chemicals and solvents were of reagent

71

grade and were used without further purification.

72

2.2. Preparation of carvedilol-loaded solid dispersions

73

Solid dispersions were prepared using the solvent evaporation method [12]. Polymers and CAR

74

with different ratios were completely dissolved in ethanol, and the weight ratios between the drug and

75

excipient were designed as shown at Table 1. The above solution was mixed and organic solvent was

76

removed by rotary evaporation. The resulting substance was dried in vacuum oven for 48 h at 80℃,

77

ground carefully, and sieved (60 mesh) to obtain CAR SDs.

78

2.3. Physicochemical characterization

79

2.3.1. Scanning electron microscopy (SEM)

80

The surface topographies of the pure CAR and the CAR-loaded SDs were observed using a

81

scanning electron microscope (S-3400N, Hitachi). The powders were fixed to a brass specimen holder

82

using double-sided adhesive tape and were made electrically conductive by coating with gold (6

83

nm/min) in a vacuum (6 Pa), using a Hitachi Ion Sputter (E-1030) for 300 s at 15 mA. 3

84

2.3.2. X-ray diffraction analysis (XRD)

85

X-ray diffraction (XRD) patterns (Rigaku Smart Lab, Japan) were recorded using a powder X-ray

86

diffractometer. Diffraction patterns were obtained using a step width of 0.02˚ with a detector resolution

87

in 2θ between 5-40˚ and a scan speed of 2 s per step at 25 ℃ [13].

88

2.4. Dissolution properties

89

2.4.1. In vitro dissolution studies

90

In vitro dissolution studies of pure carvedilol, physical mixture (PM), and solid dispersions (SDs)

91

were carried out using the United States Pharmacopeia (USP) Apparatus II paddle method (100 rpm,

92

37℃, and 900 mL dissolution medium) with a ZRS-8G dissolution tester (Shanghai, China) [14].

93

Roughly 10 mg of sample powder was placed in the dissolution medium and 5 mL of artificial

94

intestinal fluid (pH 6.8 phosphate buffer solution) and artificial gastric fluid (pH 1.2 hydrochloric acid

95

solution) was withdrawn 10, 20, 30, 40, 50, 60, 90, 120 and 180 min prior to filtration using a 0.45 µm

96

filter. The concentration of samples was analyzed using an ultraviolet spectrophotometer (756 PC

97

UV-2200, Shanghai, China) at 240 nm. All measurements were repeated three times.

98

In order to further study the kinetic release of CAR, DDSolver software [15] was used to fit the

99

following kinetic models: Zero-order, First-order, Korsmeyer–Peppas, Makoid, Peppas–Sahlin, and

100

Weibull.

101

2.4.2. Storage stability experiment

102

Freshly prepared solid dispersions including IR3, HIR2, and MIR2, and the solid dispersions were

103

kept for two months at 25℃ and 60% relative humidity (RH), and were analyzed for in vitro dissolution

104

to evaluate the storage stability of the CAR SDs. Besides, the moisture analysis was conducted to

105

confirm the storage stability of SDs with the different RH ranging from 10% to 90% respectively. The

106

methodology used in for the in vitro dissolution experiments was the same as is detailed in Section

107

2.4.1. All tests were repeated three times.

108

2.5. Molecular docking of CAR/Kollicoat IR-SD

109

AutoDock 4.0 software was employed to assess the molecular interactions of CAR/Kollicoat

4

110

IR-SD by molecular docking. The molecular docking results of the Kollicoat IR and CAR molecules

111

were analyzed by Discovery Studio Visualizer 4.5 and the Discovery Studio Visualizer 4.5 was also

112

used for molecular interaction analysis (http://accelrys.com/products/discovery-studio/) [16]. The

113

molecular structures of pure CAR and the polymer Kollicoat IR are shown in Figures 1a and 1d,

114

created using the SYBYL 6.9.1 software package (Tripos Inc. St. Louis, MO, USA). The optimal

115

parameters were as follows: the maximum number of interactions was 10,000, and the frequency of

116

energy variety was 0.005 kcal/ (mol × Å).

117

The preferred parameters of the AutoDock 4.0 software were as follows: the maximum number of

118

energy assessments was raised to 25,000,000, the interactions of the Solis & Wets local search were

119

3000, the number of individuals in a population was 300, and the number of generations was 100.

120

Results differing by < 2Å in positional root mean square deviation were clustered together [17]. In

121

every group, the lowest binding energy configure ration with the highest frequency percentage was

122

chosen as the symbol of the group. All other parameters were set at the default values.

123

2.6.

124

2.6.1. Determination of critical micelle concentration (CMC)

Effect of HPMC, MC on CAR SDs

125

Different concentrations of surfactant solution were prepared, and the maximum bubble pressure

126

method (Figure 2) was used to determine the critical micelle concentration (CMC) values for the single

127

polymer and binary polymers systems [18]. When surface adsorption reaches saturation, corresponding

128

to the concentration where the surface is no longer saturated, the curve reaches a turning point, and the

129

concentration at this point is the critical micelle concentration [19]. The measured surface tension

130

values were accurate to within ±0.1 mN·m-1. The CMC values were determined by plotting γ as a

131

function of the logarithm values (log C) of the surfactant solution concentrations over a wide

132

concentration range [20], as shown in Figure 8.

133

2.6.2. Evaluation of solubilization ability

134

The differences in the molar solubilization ratios (MSR) and the partition coefficients (Kmic) of

135

HPMC, MC, HIR5, and MIR4 between the micelle and water suggested the solubilization capacity of

136

the surfactants. A large number of experiments on the solubilization of CAR with single surfactants 5

137

HPMC, and MC and with two kinds of different surfactants in mixed systems with varying ratios were

138

performed [20]. The excess amounts of CAR were added into HPMC, MC, HIR5, and MIR4 solutions

139

of different concentrations. The solubilization ability was determined by adding 3 mL phosphate buffer

140

(pH 6.8) into the above solutions and placing the resulting mixture into 10-mL tubes. Then, tubes were

141

equilibrated at 37 °C for 48 h in a thermostatic tank at about 110 rpm. Samples were then centrifuged at

142

9000 g for 20 min to discard the excess crystalline particles. Finally, the solutions were analyzed by

143

using 756 PC UV-2200 spectrophotometers (Shanghai, China) at a wavelength of 240 nm.

144

2.7. Statistical analysis

145

All data were analyzed using Graphpad Prism 7 (GraphPad Software, San Diego, CA) using

146

two-tailed Student’s test. All experiments were performed in triplicate unless otherwise mentioned.

147

Error bars used in this work are SD. p < 0.05 is statistically significant.

148

3. Results and discussion

149

3.1. Scanning electron microscopy (SEM)

150

SEM images of pure CAR, Kollicoat IR, CAR/Kollicoat IR 1:5-SD, CAR/HPMC/Kollicoat IR

151

1:1.67:3.33-SD, and CAR/MC/Kollicoat IR 1:1.25:3.75-SD are shown in Figure 3. Pure CAR was

152

observed as flake-shaped, indicating a crystalline form (Figure 3a). Kollicoat IR was in a spherical

153

granular form (Figure 3b). However, when CAR was loaded into SDs, the crystalline form of CAR

154

disappeared (Figure 3c, Figure 3d and Figure 3e), which indicated that CAR present in the SDs

155

prepared by the solvent evaporation method was in an amorphous state. Thus, CAR was adsorbed on

156

the excipients successfully by making CAR-SDs [2].

157

3.2. X-ray diffraction analysis (XRD)

158

XRD was also used to analyze the crystallization of CAR in solid dispersions. On the one hand,

159

the diffractograms showed amorphous halos and no crystalline peaks for CAR-loaded SDs (Figure 4),

160

indicating the complete amorphous state of the SDs, which was in agreement with the SEM images.

161

The diffractogram of PM of single carriers also showed no diffraction peak apart from the Kollicoat IR

162

peaks at about 20˚(2θ), demonstrating that the corresponding surfactants were also transformed to an

163

amorphous state. Crystalline CAR (Figure 3a) and PMs, on the other hand, showed the expected 6

164

characteristic crystalline diffraction peaks at 2θ of 6˚,11˚,13˚,17˚,18˚,24˚,26˚ and 29˚, suggesting that

165

untreated CAR exists in a crystalline state [21].

166

3.3. Dissolution properties

167

3.3.1. In vitro dissolution

168

An in vitro release study was performed to determine the most appropriate vehicle in the

169

construction of the CAR SDs [8]. Dissolution profiles of prepared solid dispersions in artificial gastric

170

fluid (pH 1.2 hydrochloric acid solution) and artificial intestinal fluid (pH 6.8 PBS) are presented in

171

Figure 5. It was noted that the CAR SD with the Kollicoat IR at a ratio of 1:5 improved the solution of

172

CAR compared to the other ratios in pH 6.8 PBS. However, dissolution rate at 3h has been improving

173

approximately one-fold by addition HPMC or MC as surfactants. Furthermore, both HIR5 and MIR4

174

also improved CAR dissolution rate. The cumulative percentage of MIR3 reached over 80% within 10

175

min, and MIR3 also improved dissolution rate. Compared to the traditional carriers of solid dispersion

176

such as HPMC, HPMCP, PVP and so on[10], the binary polymer system could improve the dissolution

177

more effectively, which can be attributed to the combined action of MC and HPMC as micelles and

178

Kollicoat IR, respectively. Furthermore, less CAR release in hydrochloric acid solution (pH 1.2) means

179

significantly reduced gastric stimulation, which is helpful in promoting compliance of patients.

180

As is shown in Table 2, the release profiles of CAR, IR3, HIR2, and MIR2 are fitted to

181

Makoid-Banakar, First-order equations, which were better than the other kinetic models fitted.

182

3.3.2. Storage Stability

183

In vitro dissolution tests and moisture analysis of CAR SDs were determined again after two

184

months and the results are shown in Figure 6 and Table 3. As shown in Table 3, the cumulative drug

185

release of CAR SDs including IR3, HIR2, and MIR2 that had been stored for two months decreased

186

slightly (approximately 3.05%, 1.09%, and 0.91%, respectively) compared to the freshly prepared SDs,

187

and the optimized group was MIR2. The results shown in Figure 6 indicated that during the storage

188

process SDs were extremely stable and the carrier Kollicoat IR probably maintained the stability due to

189

the characteristic hydrogen bonding between CAR and Kollicoat IR [22]. According to the results of

190

other groups compared to IR3, the other groups may exhibit the same mechanism as Kollicoat IR but

7

191

the MIR2 group has stronger molecular interactions.

192

3.4. CAR–Kollicoat IR interactions in molecular docking simulation

193

Kollicoat IR as a carrier of SD effectively improved dispersibility of the drug by molecular

194

interactions. The interaction between the carrier and the drug obviously reduced reaggregation and

195

agglomeration of the drug, thereby increasing drug dissolution rate and improving bioavailability. In

196

Figure 7, the interactions of CAR with Kollicoat IR are shown at the molecular level, with both the

197

polymer and the drug in skeleton and electron cloud views. In general, the polymer going through a

198

hydrophobic interaction with the drug induce the free energy; according to thermodynamics, negative

199

free energy (△G<0) indicates a relatively stable system, while the opposite (△G>0) is an unstable

200

system during the drug dispersion in the polymer. The bonding energy value of the drug and polymer

201

was −4.33 kcal/mol, proving that CAR had an interaction with Kollicoat IR through the formation of

202

hydrophobic bonds instead of the single molecules becoming aggregated.

203

3.5. Effect of HPMC, MC on CAR SDs

204

3.5.1. Critical micelle concentration

205

The minimum surface tension and the CMC are highly important parameters for the

206

characterization of surfactants [23]. Surfactants have saturation solubility in a special solution and no

207

longer dissolve after reaching the saturation. However, designing a surfactant according to the principle

208

of CMC can greatly increase the solubility. Thus, the maximum bubble pressure method was used to

209

determine the CMCs of HPMC, MC, HIR5, and MIR4. The surface tension of aqueous surfactant

210

solutions initially decreases sharply with the increase in the solution concentration, but changes slowly

211

or shows no change after reaching a certain concentration (CMC). Therefore, the inflection points of

212

the curves of surface tension against the logarithm of the surfactant concentration were taken as CMC

213

values. Figure 8 shows that MC had the highest surface tension, followed by MIR4, HPMC, and finally

214

HIR5. CMC values can be calculated according to Eq. (1), as shown in Table 4.

215

∆௛

∆௛ೢ

=



ఊೢ

,

(1)

216

where ∆ℎ is the liquid column height difference of surfactants, ∆ℎ௪ is the liquid column height

217

difference of water, γ is the surface tension of surfactants, and ߛ௪ is the surface tension of water. All 8

218

the values are measured at same temperature (25°C).

219

3.5.2. Solubilization calculation

220

A useful method to evaluate the effectiveness of surfactants at solubilizing a given substance is to

221

calculate the molar solubilization ratios (MSR) and the partition coefficients (Kmic). MSR is defined as

222

the number of moles of the organic compound solubilized per mole of the micellized surfactant[20].

223

The MSR can be calculated using Eq. (2), ௌ೟ ିௌ಴ಾ಴

224

MSR =

225

In this formula, Ct represents the molar concentration of the surfactant solution at concentrations

226

greater than the CMC, Scmc is the molar solubility of CAR when the surfactant concentration is equal to

227

the CMC, and St is the total apparent molar solubility of CAR in the surfactant solution corresponding

228

to Ct.

஼೟ ି஼ெ஼

,

(2)

229

According to the phase separation model of micellar solubilization, the micelle-water partition

230

coefficient (Kmic) is used to describe the effectiveness of solubilization. A partition coefficient, Kmic,

231

exists between the micellar phase and the aqueous phase [23]. Its relationship to the MSR is described

232

as follows: ௑೘೔೎

233

‫ܭ‬௠௜௖ =

234

where Xmic is the molar concentration of the micellar phase, and Xw is the methane molar

235

௑ೢ

,

(3)

concentration of the aqueous phase. ெௌோ

236

ܺ௠௜௖ =

237

ܺ௪ = ܵ஼ெ஼ × ܸ௪ ,

238

In this equation, Vw is the mole volume of water equal to 0.01805 L·mol-1 at 25°C.

239

Rearranging Eqs. (3)-(5), Kmic can be expressed as:

240

‫ܭ‬௠௜௖ =

241

According to Eq. (2) and the CMC values of the surfactant, a liner fitting method was used to

242

calculate the MSR of HPMC, MC, HIR5, and MIR4. The value of Kmic is dependent on several factors

243

including the chemistry of the surfactant, the solubilization, and the temperature of the system. The log

244

Kmic can be calculated using Eq. (6), as is shown in Table 4.

ଵାெௌோ

,

ெௌோ

(ଵାெௌோ)ௌ಴ಾ಴ ௏ೈ

(4) (5)

,

(6)

9

245

During the linear fitting process of MSR, the correlation coefficient R2 was greater than 0.95,

246

indicating that the results were highly reliable and truly reflect the solubilization ability of the different

247

surfactants. In a nonionic surfactant solution, the solubilization ability orders of MSR and Kmic were

248

MIR4 > HIR5, which has the inversely proportional relationship with solubilization ability, indicating

249

the greater solubilization ability of HIR5. These results were consistent with the dissolution results

250

detailed above.

251

3.5.3. Solubilization mechanisms

252

HPMC and MC as nonionic surfactants are both less irritating than anionic and cationic

253

surfactants. In addition, they are highly stable due to their nonionic states in solution, and they cannot

254

be degraded even in the presence of strong electrolyte inorganic salts or pH changes. Surfactants can be

255

used as crystalline inhibitors to increase the supersaturation of active pharmaceutical ingredients in

256

vivo when the concentration of solution is above the CMC. There are two steps needed to generate

257

supersaturated solutions after drug crystallization, including nucleation and crystal growth. The

258

activation energy for nucleation mainly comes from interfacial tension between the medium and the

259

small particles. The high curvature between the medium and the small particles must be overcome for

260

nucleation to occur[24]. In other words, the activation energy is not overcome until a certain degree of

261

supersaturation is reached, so no new nuclei are formed for a certain period of time. The state in which

262

no nuclei are formed is called metastable. On the one hand, HPMC and MC maybe expand this region.

263

The uniform nucleation rate of pellets (J) is given by Eq. (7), య ଵ଺గ௩ య ఊ೙ೞ

264

J = A݁‫ ݌ݔ‬ቂ−

265

where v is the molecular volume of the crystalline solute, A is the exponential pre-kinetic factor, T

266

is the absolute temperature, S is the degree of supersaturation, and γns is the interface energy between

267

the solvent and the nucleus [4].

ଷ(௞்)య (୪୬ ௌ)మ

ቃ,

(7)

268

Therefore, non-surface-active compounds that increase solubility could explicitly reduce the

269

nucleation rate by influencing the degree of supersaturation. At the same time, the interfacial tension

270

will decrease in the presence of surfactants. On the other hand, the condition of surfactants dispersed in

271

SDs are shown in Scheme 1. Surfactants have hydrophobic group ends and hydrophilic group ends,

272

when the surfactant is put into the water, hydrophobic group will be positioned toward the air and the

10

273

hydrophilic group is positioned downward. Once the surfactant solution reaches saturation, a micelle is

274

formed. On the outside of the micelle is a hydrophilic group, and on the inside is a hydrophobic group.

275

Due to the hydrophobicity of CAR SD, they will be encapsulated into the micelle, thus increasing the

276

solubility of CAR SD in the solution [25].

277

4. Conclusions

278

CAR SDs were reformulated with Kollicoat IR, Kollicoat IR/HPMC, and Kollicoat IR/MC

279

carriers using the solvent evaporation method. The obtained results suggest that HPMC and MC as

280

both uncommon nonionic surfactants and auxiliary excipients maintain good stability and solubilization

281

ability. Moreover, a molecular docking simulation showed that intermolecular interaction occurred and

282

suggested a relatively stable system. This is the first study in which Kollicoat IR was used as carrier to

283

prepare CAR SDs. In vitro cumulative drug release of CAR was significantly improved by about 30%,

284

and the addition of HPMC and MC further greatly enhanced the dissolution rate. In brief, CAR solid

285

dispersions with HPMC and MC added to Kollicoat IR as binary polymer systems have great potential

286

for pharmaceutically effective oral drug formulation. This study may provide a new view for designing

287

different formulations to improve dissolution ability in the future.

288

Acknowledgement

289 290

Authors acknowledge Head Chemical Reagent Corporation (Shandong, China) for gift sample of methylcellulose.

291

References

292

[1] Raja H.K.P., Suresh B., Raju J. & Prabhakar R.V.. Solubility Enhancement and Physicochemical

293

Characterization of Carvedilol Solid Dispersion with Gelucire 50/13. Archives Pharmacal Research,

294

2011,3(34), 51-57.

295

[2] Sung N.L., Bijay K.P., Tuan H.T., Nirmal M., Roshan P., Young I.L., Dong W.L., Jong S.W., Han G.

296

Choi, C., Soon Y., Jong O.K. et al. A novel surface-attached carvedilol solid dispersion with enhanced

297

solubility and dissolution. Archives Pharmacal Research, 2013,1(36), 79-85.

298

[3] Rehab N.S. & Mona B. Soluplus®: A novel polymeric solubilizer for optimization of Carvedilol

299

solid dispersions: Formulation design and effect of method of preparation. Powder Technology, 11

300

237(2013), 406-414.

301

[4] Daniel J. E., Dave A.M., Sandra U.K. & Robert O.W. Improved vemurafenib dissolution and

302

pharmacokinetics as an amorphous solid dispersion produced by KinetiSol® processing. American

303

Association of Pharmaceutical Scientists, 19(2018), 1957-1969.

304

[5] Gong, W., Wang, Y., Sun, L., Yang, J., Shan, L., Yang, M., Gao, C. Development of Itraconazole

305

liquisolid compact: effect of polyvinylpyrrolidone on the dissolution properties. Current Drug Delivery,

306

2016,13(3), 452-461.

307

[6] Venkateswarlu K., Preethi J.K. & Chandrasekhar K.B. Enhancement of loperamide dissolution rate

308

by liquisolid compact technique. Advanced Pharmaceutical Bulletin, 2-016,6(3), 385-390.

309

[7] Chae G.S., Lee J.S., Kim S.H., Seo K.S., Kim M.S., Lee H.B., Khang G. Enhancement of the

310

stability of BCNU using self-emulsifying drug delivery systems (SEDDS) and in vitro antitumor

311

activity of self-emulsified BCNU-loaded PLGA wafer. International Journal of Pharmaceutics,

312

2005,301(1-2), 6-14.

313

[8] Ahlam Z.A., Rania H., Sara A.M., Areej K., Rana A.H., Islam H. Nanoemulsion-based film

314

formulation for transdermal delivery of carvedilol. Journal of Drug Delivery Science and

315

Technology,2018,8(46),122-128.

316

[9] Fan, N., Ma, P.P., Wang, X., Li, C., Zhang, X.R., Zhang, K.X., Li, J. Storage stability and

317

solubilization ability of HPMC in curcumin amorphous solid dispersions formulated by Eudragit E100.

318

Carbohydrate Polymers, 199(2018), 492-498.

319

[10] Jung B.S., Min J.K., Seul J.K., Su J.K., Ji H.L., Hyeong S.K., Dongwon L., Gilson K. Dissolution

320

properties of control released solid dispersion of carvedilol with HPMC and Eudragit RS. Journal of

321

Pharmaceutical Investigation, 42(2012), 285-291.

322

[11] Jaydip V., Heta D., Suhas G. G., John T., Donald K., Damon D., Abu T.M.S. Development of solid

323

dispersion by hot melt extrusion using mixtures of polyoxylglycerides with polymers as carriers for

324

increasing dissolution rate of a model poorly soluble drug. Journal of Pharmaceutical Sciences,

325

2018,2(108), 888-896.

326

[12] Dong K.L., Jeong W.B., Byung J.S., Hansu J., Hyoung E.K., Dongwon L., Gilson K. Effect of

327

manufacturing method and acidifier on the dissolution rate of carvedilol from solid dispersion

328

formulations. Journal of Pharmaceutical Investigation, 41(2011), 363-369.

329

[13] Renata A.V., Monica S., Isidoro C. & Martin K. Early stages of drug crystallization from 12

330

amorphous dispersion via fractal analysis based on chemical imaging. European Journal of

331

Pharmaceutics and Biopharmaceutics, 2018,12(133), 122-130.

332

[14] Jelena D., Stoja M., Djordje M., Vladimir D., Aleksandra D., Svetlana I. Selection of the suitable

333

polymer for supercritical fluid assisted preparation of carvedilol solid dispersions. International Journal

334

of Pharmaceutics, 554(2019), 190-200.

335

[15] Zhang, Y., Huo, M., Zhou, J., Zou, A., Li, W., Yao, C., Xie, S. DDSolver: An Add-In Program for

336

Modeling and Comparison of Drug Dissolution Profiles. AAPS JOURNAL, 2010,12(3),263-271.

337

[16] Prashamsa K., Su H. S., Hyun A. J. & Jae S. C. Comparative molecular docking studies of lupeol

338

and lupenone isolated from Pueraria lobata that inhibits BACE1: Probable remedies for Alzheimer's

339

disease. Asian Pacific Journal of Tropical Medicine, 2017,10(12), 1117-1122.

340

[17] Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J.

341

Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility, J. Comput.

342

Chem., 2009,30(16), 2785-2791.

343

[18] Xu, L.M., Mo, C.S., & Xu, X.Y. Experimental exploration on determination of surface tension of

344

aqueous solution by maximum bubble pressure method. University laboratory work research, 4(2009),

345

35-37.

346

[19] Charles S., Jian R.L., Robert K. T., Ian M.T., John R.P.W., Mario C. M. Chain modelling of

347

surfactant critical micelle concentration and surface composition. ACS Paragon Plus Environment,

348

10(2018), 1-28.

349

[20] Song, D.D., Liang, S.K., Yan, L.L., Shang, Y.J. & Wang, X.L. Solubilization of polycyclic

350

aromatic hydrocarbons by single and binary mixed rhamnolipid-sophorolipid biosurfactants. Journal of

351

Environmental Quality, 45(2016), 1405-1412.

352

[21] Sung J.K., Hong K.L., Young G.N., Ki H.B., Hye J. L., Miao W., Hyun W.H., Cheong W. C. A

353

novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal

354

permeability. International Journal of Pharmaceutics, 555(2019), 11-18.

355

[22] K. Wlodarskia, W. Sawickia, K. Habera, J. Knapikb, Z. Wojnarowskab, M. Paluchb, Lepekc,

356

Hawelekd, L. Tajber. Physicochemical properties of tadalafil solid dispersions of polymer on the

357

apparent solubility and dissolution rate of tadalafil. European Journal of Pharmaceutics and

358

Biopharmaceutics, 2015,8(94), 106-115.

359

[23] Zhou, Z., Zhu, S.B., Gong, J.H., Zhu, M.X. & Luo, W.T. Experimental study on methane 13

360

solubilization by organic surfactant aggregates. Chemical Papers, 72(2018), 1467-1475.

361

[24] Smruti P.C. & Rohit P.D. Application of surfactants in solid dispersion technology for improving

362

solubility of poorly water-soluble drugs. Journal of Drug Delivery Science and Technology,

363

2017,10(41), 68-77.

364

[25] L. Catalina Cabana Saavedra, Erica M. P. G., Rafael G. O., Mariana A. F. Aggregation behavior

365

and solubilization capability of mixed micellar systems formed by a gemini lipoamino acid and a

366

non-ionic surfactant. Colloids and Surfaces A, 533(2017), 41-47.

14

Table 1 Formulation compositions of CAR SDs and some relevant physical mixture (PM) with different weigh ratios. The weight ratio between drug and binary polymers (Kollicoat IR /HPMC and Kollicoat IR /MC) was 1:5. Single polymer Batch no.

Binary polymers ratios

Drug Kollicoat IR

Kollicoat IR /HPMC

Kollicoat IR /MC

IR 1

1

1

IR 2

1

3

IR 3

1

5

HIR 1

1

1/1

HIR 2

1

2/1

HIR 3

1

3/1

HIR 4

1

5/1

HIR5 (PM)

-

2/1

MIR1

1

1/1

MIR2

1

3/1

MIR3

1

5/1

MIR4 (PM)

-

3/1

Table 2 The kinetic release rate of and R2 coefficients of CAR and prepared solid dispersions obtained from release data fitting analyses based on kinetic equations. Kinetic Equations

CAR

IR3

HIR2

MIR2

Zero-order

 = 16.568 + 0.262

 = 52.049 + 0.068

 = 56.547 + 0.164

 = 71.589 + 0.243

 =  +  

R2=0.9240

R2=0.2992

R2=0.4767

R2=0.4439

First-order

 = 59.423 × [1 −  . ]

 = 62.797 × [1 −  .  ]

 =  × [1 −   ]

R2=0.9345

R2=0.9456

R2=0.9897

R2=0.9937

Korsmeyer-Peppas

 = 4.546 ×  .#$

 = 34.976 ×  .%

 = 32.940 ×  .%

 = 38.691 ×  .%

 =  × "

R2=0.9940

R2=0.6388

R2=0.7682

R2=0.7339

 = 17.051 .&# ×  .#

 = 16.751 .#% ×  .#

 = 15.643 .!%# ×  .!

 = 2.755 .

Makoid-Banakar

!

×  .%

 = 76.192 × [1 −  .

 ]

 = 102.048 × [1 −  .! ]

 =  " ×  

R2=0.9964

R2=0.9903

R2=0.9444

R2=0.9469

Peppas-Sahlin

 = 4.623 .! − 0.012

 = 13.993 .! − 0.725

 = 15.310 .! − 0.727

 = 19.679 − 0.913

 =   .! + % 

R2=0.9881

R2=0.9562

R2=0.9360

R2=0.9352

 = 100{1 −  [(

Weibull  = 100{1 −  ((

* )⁄, .

}

0.123 )⁄&%.&&$]

}  = 100{1 −  ((

R2=0.9948

0.456 )⁄%.

R2=0.6814

$ .

}  = 100{1 −  ((

0.760 )⁄&.%.

}  = 100{1 −  ((

R2=0.8360

5.541 )⁄%#.&.

R2=0.9936

Table 3 The evaluation of storage stability of different formulations (mean ± SD, n=3). Groups

Before 2 months

After 2 months

Difference value

Stability

IR3

54.55±3.60%

57.60±0.05%

-3.05±0.05%

Good

HIR2

66.22±1.09%

65.55±0.43%

-1.09±0.67%

Good

MIR2

87.76±0.71%

86.85±1.77%

-0.91±0.71%

Excellent

}

Table 4 CMC, MSR and log Kmic values for different surfactants. Samples

HPMC

MC

HIR5

MIR4

CMC (mg/mL)

0.1

0.4

0.08

0.2

MSR

0.0004

0.0007

0.0016

0.0024

log Kmic

2.42

2.59

2.95

3.18

Figure 1. Chemical structures of the (a) pure CAR and the monomer units of (b) HPMC, (c) MC and (d) Kollicoat IR

Figure 2. The equipment of maximum bubble pressure method to determine CMC.

Figure 3. SEM images of (a) pure CAR, (b)Kollicoat IR, (c) IR3, (d) HIR2, (e) MIR2. Scale bar is shown in the graph.

Figure 4. X-ray powder diffraction of (a) pure CAR, (b) Kollicoat IR, (c) PM of IR3, (d) IR3, (e) HIR5, (f) PM of HIR2, (g) HIR2, (h) MIR4, (i) PM of MIR2 (l) MIR2.

Figure 5. Dissolution profiles of CAR solid dispersions in pH 6.8 PBS with (a) different ratios of Kollicoat IR and CAR , (b) addition of surfactants. (c) dissolution profiles of CAR solid dispersions in pH 1.2 hydrochloric acid solution. (mean ± SD, n=3). *p<0.05, **p<0.01 and ***p<0.001 compared to the CAR group.

Figure 6. In vitro dissolution and moisture analysis of CAR SDs with different carriers that have stored for two months (mean ± SD, n=3). (a) IR3; (b) HIR2; (c) MIR2; (d) Weight gain of different solid dispersions (mean ± SD, n=3).

Figure 7. Docking conformation of carvedilol complexed with Kollicoat IR. CAR and polymer are both shown in 3D structure representation. Two different views of integral conformations relevant with polymer, called CAR-Kollicoat IR SD, were displayed with the molecule and polymer shown.

Figure 8. Plots of surface tension (γ) as a function of the logarithm values of the total surfactant concentration (log C) of the single and different mixed CAR SDs systems with different concentration in the solution.

Scheme 1. Possible solubilization mechanism of surfactants.

1. The solubilization mechanism of surfactants added to SDs were clearly illustrated. 2. Kollicoat IR was the first time used as carrier to prepare CAR SDs. 3. The molecular modeling explained the reason why improved solubility in vitro.